

## Doravirine Formulation

Version 5.0      Revision Date: 05/09/2026      SDS Number: 58373-00031      Date of last issue: 12/06/2025  
Date of first issue: 02/16/2015

### SECTION 1. IDENTIFICATION

Product name : Doravirine Formulation  
Other means of identification : No data available

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Not a hazardous substance or mixture.

#### GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

#### Other hazards

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	Common Name/Synonym	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Cellulose	No data available	9004-34-6*	>= 10 - <= 30	TSC
Doravirine	3-Chloro-5-((1-((4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benz	1338225-97-0*	>= 7 - <= 13	TSC
Magnesium stearate	Octadecanoic	557-04-0*	>= 0.5 - <= 1.5	TSC

## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
5.0	05/09/2026	58373-00031	Date of first issue: 02/16/2015

	acid, magnesium salt (2:1)		
--	----------------------------	--	--

\* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : No special precautions are necessary for first aid responders.
- Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Halogenated compounds  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
5.0	05/09/2026	58373-00031	Date of first issue: 02/16/2015

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.  
Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## Doravirine Formulation

Version 5.0      Revision Date: 05/09/2026      SDS Number: 58373-00031      Date of last issue: 12/06/2025  
Date of first issue: 02/16/2015

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Total dust)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (total dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Doravirine	1338225-97-0	TWA	500 ug/m <sup>3</sup> (OEB2)	Internal
Magnesium stearate	557-04-0	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Inhalable)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (Respirable)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (inhalable dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWAEV (respirable aerosol fraction)	3 mg/m <sup>3</sup>	CA QC OEL
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

#### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
5.0	05/09/2026	58373-00031	Date of first issue: 02/16/2015

---

Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	off-white
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
5.0	05/09/2026	58373-00031	Date of first issue: 02/16/2015

---

Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

## Doravirine Formulation

Version 5.0      Revision Date: 05/09/2026      SDS Number: 58373-00031      Date of last issue: 12/06/2025  
Date of first issue: 02/16/2015

---

### Components:

#### **Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

#### **Doravirine:**

Acute oral toxicity : LD50 (Rat): > 750 mg/kg  
Remarks: No mortality observed at this dose.  
  
(Rat): Method: Phototoxicity  
Remarks: No evidence of phototoxicity was observed  
  
LD50 (Dog): > 1,000 mg/kg  
Remarks: No mortality observed at this dose.  
  
LD50 (Mouse): > 450 mg/kg  
Remarks: No mortality observed at this dose.

#### **Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

#### **Skin corrosion/irritation**

Not classified based on available information.

### Components:

#### **Doravirine:**

Remarks : No data available

#### **Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

#### **Serious eye damage/eye irritation**

Not classified based on available information.

## Doravirine Formulation

Version 5.0      Revision Date: 05/09/2026      SDS Number: 58373-00031      Date of last issue: 12/06/2025  
Date of first issue: 02/16/2015

---

### Components:

#### **Doravirine:**

||Remarks : No data available

#### **Magnesium stearate:**

||Species : Rabbit  
||Result : No eye irritation  
||Remarks : Based on data from similar materials

### **Respiratory or skin sensitization**

#### **Skin sensitization**

Not classified based on available information.

#### **Respiratory sensitization**

Not classified based on available information.

### Components:

#### **Doravirine:**

||Remarks : No data available

#### **Magnesium stearate:**

||Test Type : Maximization Test  
||Routes of exposure : Skin contact  
||Species : Guinea pig  
||Method : OECD Test Guideline 406  
||Result : negative  
||Remarks : Based on data from similar materials

### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Cellulose:**

||Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
  
||Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

#### **Doravirine:**

||Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

## Doravirine Formulation

Version 5.0      Revision Date: 05/09/2026      SDS Number: 58373-00031      Date of last issue: 12/06/2025  
Date of first issue: 02/16/2015

---

Genotoxicity in vivo : Result: negative  
Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: negative  
: Test Type: Micronucleus test  
Species: Rat  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

### **Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials  
Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials  
Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

### **Carcinogenicity**

Not classified based on available information.

### **Components:**

#### **Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

#### **Doravirine:**

Species : Mouse  
Application Route : Oral  
Exposure time : 6 Months  
Result : negative  
Remarks : No significant adverse effects were reported

### **Reproductive toxicity**

Not classified based on available information.

### **Components:**

#### **Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Doravirine Formulation

Version 5.0      Revision Date: 05/09/2026      SDS Number: 58373-00031      Date of last issue: 12/06/2025  
Date of first issue: 02/16/2015

---

Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

### Doravirine:

Effects on fertility : Test Type: Fertility  
Species: Rat, male and female  
Fertility: NOAEL: 450 mg/kg body weight  
Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 450 mg/kg body weight  
Result: No adverse effects.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 300 mg/kg body weight  
Result: No adverse effects.

### Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

Not classified based on available information.

### Repeated dose toxicity

### Components:

#### Cellulose:

Species : Rat

## Doravirine Formulation

Version 5.0      Revision Date: 05/09/2026      SDS Number: 58373-00031      Date of last issue: 12/06/2025  
Date of first issue: 02/16/2015

---

NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

### Doravirine:

Species : Rat  
NOAEL : 450 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL :  $> 450$  mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL :  $> 1,000$  mg/kg  
Application Route : Oral  
Exposure time : 9 Months  
Remarks : No significant adverse effects were reported

### Magnesium stearate:

Species : Rat  
NOAEL :  $> 100$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### Doravirine:

Ingestion : Symptoms: confusion, Headache, Dizziness, Nausea, Rash, abnormal dreams, flushing, Neurological disorders, mental depression

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### Cellulose:

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)):  $> 100$  mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Doravirine Formulation

Version 5.0      Revision Date: 05/09/2026      SDS Number: 58373-00031      Date of last issue: 12/06/2025  
Date of first issue: 02/16/2015

II

### Doravirine:

- |  |   |  |
|--|---|--|
| Toxicity to daphnia and other aquatic invertebrates                    | : | EC50 (Americamysis): 9.1 mg/l<br>Exposure time: 96 h   |
| Toxicity to algae/aquatic plants                                       | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 5.8 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201<br>Remarks: No toxicity at the limit of solubility.<br><br>NOEC (Pseudokirchneriella subcapitata (green algae)): 5.8 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201<br>Remarks: No toxicity at the limit of solubility. |
| Toxicity to fish (Chronic toxicity)                                    | : | NOEC (Pimephales promelas (fathead minnow)): 1 mg/l<br>Exposure time: 32 d<br>Method: OECD Test Guideline 210<br>Remarks: No toxicity at the limit of solubility.  |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC (Daphnia magna (Water flea)): 0.38 mg/l<br>Exposure time: 21 d<br>Method: OECD Test Guideline 211<br>Remarks: No toxicity at the limit of solubility.   |
| Toxicity to microorganisms   | : | EC50: > 1,000 mg/l<br>Exposure time: 3 h<br>Test Type: Respiration inhibition<br>Method: OECD Test Guideline 209<br><br>NOEC: 1,000 mg/l<br>Exposure time: 3 h<br>Test Type: Respiration inhibition<br>Method: OECD Test Guideline 209   |

### Magnesium stearate:

- |   |   |  |
|---|---|--|
| Toxicity to fish                                    | : | LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l<br>Exposure time: 48 h<br>Method: DIN 38412<br>Remarks: Based on data from similar materials   |
| Toxicity to daphnia and other aquatic invertebrates | : | EL50 (Daphnia magna (Water flea)): > 1 mg/l<br>Exposure time: 47 h<br>Test substance: Water Accommodated Fraction<br>Method: Directive 67/548/EEC, Annex V, C.2.<br>Remarks: Based on data from similar materials<br>No toxicity at the limit of solubility. |
| Toxicity to algae/aquatic plants                    | : | EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l   |

## Doravirine Formulation

Version 5.0      Revision Date: 05/09/2026      SDS Number: 58373-00031      Date of last issue: 12/06/2025  
Date of first issue: 02/16/2015

---

	Exposure time: 72 h
	Test substance: Water Accommodated Fraction
	Method: OECD Test Guideline 201
Remarks: Based on data from similar materials	
No toxicity at the limit of solubility.	
NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l	
Exposure time: 72 h	
Test substance: Water Accommodated Fraction	
Method: OECD Test Guideline 201	
Remarks: Based on data from similar materials	
Toxicity to microorganisms	: EC10 (Pseudomonas putida): > 100 mg/l
	Exposure time: 16 h
	Test substance: Water Accommodated Fraction
	Remarks: Based on data from similar materials

### Persistence and degradability

#### Components:

##### Cellulose:

||| Biodegradability : Result: Readily biodegradable.

##### Doravirine:

||| Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 2 %  
Exposure time: 28 d

##### Magnesium stearate:

||| Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

### Bioaccumulative potential

#### Components:

##### Doravirine:

||| Partition coefficient: n-octanol/water : log Pow: 2.08

##### Magnesium stearate:

||| Partition coefficient: n-octanol/water : log Pow: > 4

### Mobility in soil

#### Components:

##### Doravirine:

||| Distribution among environmental compartments : log Koc: 2.86

## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
5.0	05/09/2026	58373-00031	Date of first issue: 02/16/2015

---

**Other adverse effects**

No data available

**Endocrine disrupting properties**

No data available

---

### SECTION 13. DISPOSAL CONSIDERATIONS

**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

### SECTION 14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation**

**TDG**

Not regulated as a dangerous good

**Special precautions for user**

Not applicable

---

### SECTION 15. REGULATORY INFORMATION

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

CA. DSL : not determined

CN IECSC : not determined

**Canadian lists**

No substances are subject to CEPA Section 84 Ministerial Conditions.

---

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
5.0	05/09/2026	58373-00031	Date of first issue: 02/16/2015

### SECTION 16. OTHER INFORMATION

#### Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWA	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/09/2026

## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
5.0	05/09/2026	58373-00031	Date of first issue: 02/16/2015

---

Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8